[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360326-105":59,"doc-detail-360326-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","predictive-value-of-pd-l1-expression-and-dmmrpmmr-status-for-immune-checkpoint-inhibitor-combined-with-chemotherapy-in-advancedrecurrent-endometrial-cancer-a-meta-analysis","Predictive value of PD-L1 expression and dMMR/pMMR status for immune checkpoint inhibitor combined with chemotherapy in advanced/recurrent endometrial cancer - a meta-analysis","","Advanced/recurrent endometrial cancer (EC) presents a major treatment challenge. Immune checkpoint inhibitor (ICI) plus chemotherapy (CT) is a promising first-line strategy, but the predictive roles of deficient/proficient mismatch repair (dMMR/pMMR) and PD-L1 expression for efficacy remain uncertain. This meta-analysis systematically evaluated whether dMMR/pMMR status and PD-L1 expression predict progression-free survival (PFS) and overall survival (OS) in advanced/recurrent EC patients receiving ICI + CT.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/predictive-value-of-pd-l1-expression-and-dmmrpmmr-status-for-immune-checkpoint-inhibitor-combined-with-chemotherapy-in-advancedrecurrent-endometrial-cancer-a-meta-analysis/360326/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/predictive-value-of-pd-l1-expression-and-dmmrpmmr-status-for-immune-checkpoint-inhibitor-combined-with-chemotherapy-in-advancedrecurrent-endometrial-cancer-a-meta-analysis/360326.png","ImageObject",300,407,{"name":92,"@type":93},"Stanford","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical question does the study address?","Question",{"text":112,"@type":113},"The study evaluates whether dMMR/pMMR status and PD-L1 expression can predict PFS and OS for advanced/recurrent endometrial cancer patients treated with immune checkpoint inhibitors combined with chemotherapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which studies and outcomes were included in the meta-analysis?",{"text":117,"@type":113},"Randomized controlled trials from PubMed, Embase, Cochrane Library, and Web of Science were synthesized, using hazard ratios with 95% confidence intervals for progression-free survival (PFS) and overall survival (OS).",{"name":119,"@type":110,"acceptedAnswer":120},"How did ICI + chemotherapy affect progression-free survival across subgroups?",{"text":121,"@type":113},"Compared with chemotherapy alone, ICI + CT significantly improved PFS in dMMR, pMMR, PD-L1-positive, and PD-L1-negative subgroups based on reported hazard ratios and confidence intervals.",{"name":123,"@type":110,"acceptedAnswer":124},"Were benefits on overall survival observed for all subgroups?",{"text":125,"@type":113},"Overall survival benefit was significant only in the dMMR subgroup, while no improvement was observed in pMMR patients.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},360326,1790787973,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},2336477552062,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Lan etal. World Journal of Surgical Oncology (2026) 24:233  \n[https://doi.org/10.1186/s12957-026-04330-6](https://doi.org/10.1186/s12957-026-04330-6)  \nWorld Journal of Surgical Oncology  \nREVIEW Open Access  \nPredictive value of PD-L1  \nexpression and dMMR/pMMR status for immune checkpoint inhibitor combined with chemotherapy in advanced/recurrent endometrial cancer: a meta-analysis  \nLifang Lan1,3†, Zhuangyan Tang1,3†, Xiongwei Yao1,3†, Hongmei Liao1† and Yihua Yang1,2*  \nAbstract  \nBackground Advanced/recurrent endometrial cancer (EC) poses a significant therapeutic challenge. Immune checkpoint inhibitor (ICI) combined with chemotherapy (CT) represents a promising first-line approach, yet the predictive value of deficient/proficient mismatch repair (dMMR/pMMR) status and PD-L1 expression in therapeutic efficacy remains unclear. This study aimed to systematically evaluate the predictive value of dMMR/pMMR status and PD-L1 expression for progression-free survival (PFS) and overall survival (OS) in patients with advanced/recurrent EC treated with ICI + CT.  \nMethods A systematic review and meta-analysis of randomized controlled trials (RCTs) from four databases (PubMed, Embase, Cochrane Library, Web of Science) was performed. PFS and OS were synthesized as hazard ratios (HRs) with 95% confidence intervals (CIs) using Review Manager 5.4.  \nResults Five RCTs (2,707 patients) were included in this meta-analysis. Compared with CT alone, ICI + CT significantly improved PFS in all subgroups: dMMR (HR = 0 . 36, 95% CI:0 .28–0.45, P \u003C 0. 00001), pMMR (HR = 0 . 78, 95% CI:0 .70–0. 87, P = 0 . 009), PD-L1-positive (HR = 0 . 52, 95% CI:0 .38–0. 70, P \u003C 0. 0001), and PD-L1-negative (HR = 0 . 66, 95% CI:0 .44–0. 98, P = 0 . 04) . For OS, only the dMMR subgroup showed a significant benefit (HR = 0 .41, 95% CI:0 .28–0. 61, P \u003C 0. 00001), with no improvement observed in pMMR patients (HR = 0 . 88, 95% CI:0 .73–1. 07, P = 0 . 20) .  \nConclusion For advanced/recurrent EC, ICI + CT enhanced PFS across dMMR/pMMR and PD-L1 expression subgroups, with OS benefit apparently confined to dMMR patients and not observed in pMMR patients. These results present the clinically valuable predictive value of MMR status for ICI + CT efficacy and suggest that PD-L1expression did not influence the benefit of ICI on patient PFS, which deserve high clinical attention.  \n†Lifang Lan, Zhuangyan Tang, Xiongwei Yao and Hongmei Liao contributed equally to this work.  \n*Correspondence: Yihua Yang [workyyh@163.com](workyyh@163.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nLan et al. World Journal of Surgical Oncology (2026) 24:233 Page 2 of 10  \nTrial registration [https://inplasy.com/inplasy-2026-03-0015/](https://inplasy.com/inplasy-2026-03-0015/), identifier INPLASY202630015 .  \nKeywords Endometrial cancer, Immu","cbCainicY0RFCrEl","https://ap.wps.com/l/cbCainicY0RFCrEl","pdf",3191498,"English","# Background\n# Methods\n# Results\n# Conclusion\n# Introduction\n## Overview of endometrial cancer burden\n## Rationale for ICI + chemotherapy","[{\"question\":\"What clinical question does the study address?\",\"answer\":\"The study evaluates whether dMMR/pMMR status and PD-L1 expression can predict PFS and OS for advanced/recurrent endometrial cancer patients treated with immune checkpoint inhibitors combined with chemotherapy.\"},{\"question\":\"Which studies and outcomes were included in the meta-analysis?\",\"answer\":\"Randomized controlled trials from PubMed, Embase, Cochrane Library, and Web of Science were synthesized, using hazard ratios with 95% confidence intervals for progression-free survival (PFS) and overall survival (OS).\"},{\"question\":\"How did ICI + chemotherapy affect progression-free survival across subgroups?\",\"answer\":\"Compared with chemotherapy alone, ICI + CT significantly improved PFS in dMMR, pMMR, PD-L1-positive, and PD-L1-negative subgroups based on reported hazard ratios and confidence intervals.\"},{\"question\":\"Were benefits on overall survival observed for all subgroups?\",\"answer\":\"Overall survival benefit was significant only in the dMMR subgroup, while no improvement was observed in pMMR patients.\"}]","Predictive value of PD-L1 expression and dMMR/pMMR status for immune checkpoint inhibitor combined with chemotherapy in advanced/recurrent endometrial cancer - a meta-analysis | PDF",1790139637,25,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7806c3aee0ba288b8d3c6cd239d84266.webp",983,1310,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8cbbaf2a3ee31dbaedd4e928cf867d0.webp",982,1309,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cfa393c2ab17854b8612e48074a00784.webp",981,1308,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/217fbc69910e51d450f78090a998547a.webp",980,1306]